Welcome to the Inaugural Therapeutic Investigator Day!
October 23, 2023 | Boston, MA | Boston Park Plaza
By invitation only
On the heels of the first-ever traditional approval of a disease-modifying therapy for Alzheimer’s, lecanemab, and the anticipated approval of donanemab early next year, it’s apparent that we have entered a new era of Alzheimer’s research. Data on multiple anti-amyloid drugs have validated that this pathway is only modestly effective, bolstering the industry-wide shift towards exploring more novel pathways centered around the biology of aging, and ensuring that this approach continues driving drug development and the next generation of therapies.
The Alzheimer’s Drug Discovery Foundation (ADDF) and our funded investigators have played a fundamental role in this shift, as the biology of aging is one of our cornerstone beliefs. We have long touted that combination therapy and precision medicine—which are needed to address the many underlying pathologies of Alzheimer’s—will be necessary to delay and halt disease progression, and eventually stop Alzheimer’s in its tracks. With the evolution of the current robust drug pipeline where over 75% of drugs in the pipeline are exploring novel pathways, the field has also arrived at this consensus.
The inaugural Therapeutic Investigator Day presents an exciting opportunity for ADDF-funded scientists to share promising updates from their research based on the biology of aging and engage in thought-provoking conversations on drug and biomarker development and prevention strategies with key thought leaders. The event will also hold forward-looking panels around the future of combination therapy and biomarkers featuring ADDF leadership, renowned scientists, and representatives from pharma and industry.
We hope Therapeutic Investigator Day facilitates networking and collaboration among our groundbreaking researchers, as we forge the path towards the next generation of Alzheimer’s drugs.
We look forward to delving into our scientists’ innovative research and uncovering new insights.
Best wishes,
 |
 |
| Howard Fillit, MD Co-Founder and Chief Science Officer Alzheimer’s Drug Discovery Foundation |
Mark Roithmayr Chief Executive Officer Alzheimer’s Drug Discovery Foundation |
ADDF's Research Portfolio
The ADDF seeks out and funds a diverse research portfolio of drug targets and biomarkers that reflect the many biological pathways and systems involved in neurodegenerative dementias, including inflammation, vascular dysfunction, misfolded proteins, and other mechanisms affected by the biology of aging that may contribute to this complex disease. Our portfolio covers diverse biomarker modalities from neuroimaging to blood tests to digital apps, and therapeutic approaches including gene therapies, biologics, small molecules, and non-pharmacologic devices. Learn more about our open funding opportunities here.
To learn more about the robust and diverse Alzheimer’s research pipeline, where over 75% of drugs target novel pathways beyond amyloid and tau, read the ADDF’s latest Clinical Trials Report.
MEETING HIGHLIGHTS
21 Speakers and Moderators
Panel Discussions
Q&A
Access to meeting by invitation only
PROGRAM
All sessions will be held in the Boston Park Plaza’s Square Room on October 23, 2023. Times below are ET.
Session/Lecture
9:00 — 9:30am
9:30 — 10:00
10:00 — 10:15
10:15 — 10:35
10:35 — 12:30
10:35 — 10:55
10:55 — 11:15
11:15 — 11:35
11:35am — 12:25pm
12:25 — 2:00
2:00 — 2:20
2:20 — 2:40
2:40 — 3:00
3:00 — 3:15
3:15 — 5:05
3:15 — 4:05
4:05 — 4:25
4:25 — 4:45
4:45 — 5:05
5:05 — 5:35
5:35 — 7:05
Chair/Speaker
9:00 — 9:30am
Mark Roithmayr - Alzheimer's Drug Discovery Foundation
9:30 — 10:00
10:00 — 10:15
10:15 — 10:35
10:35 — 12:30
10:35 — 10:55
10:55 — 11:15
11:15 — 11:35
11:35am — 12:25pm
Michael Gold, MD - Neumora
PANELISTS:
Paul Aisen, MD - USC
Miia Kivipelto, MD - Karolinska Institute
Marwan Sabbagh, MD, FAAN - Barrow Neurological Institute
Philip Scheltens, MD, PhD - EQT Life Sciences
Howard Fillit, MD - Alzheimer's Drug Discovery Foundation
12:25 — 2:00
2:00 — 2:20
2:20 — 2:40
2:40 — 3:00
3:00 — 3:15
3:15 — 5:05
3:15 — 4:05
Niranjan Bose, PhD - Gates Ventures
PANELISTS:
Nicholas Ashton, PhD - University of Gothenburg
Rhoda Au, PhD - Boston University
Dawn Matthews, MSEE, MBA - ADMdx
Howard Fillit, MD - Alzheimer's Drug Discovery Foundation
4:05 — 4:25
4:25 — 4:45
4:45 — 5:05
5:05 — 5:35
Howard Fillit, MD - Alzheimer’s Drug Discovery Foundation
5:35 — 7:05
PRESENTERS, CHAIRS, MODERATORS AND ORGANIZERS
Paul Aisen
USC
Nicholas Ashton
University of Gothenburg
Rhoda Au
Boston University
Niranjan Bose
Gates Ventures
Aaron Burstein
ADDF
Howard Fillit, MD
ADDF
Tony Giordano
Neurotherapia
Michael Gold
Neumora
Miia Kivipelto
Karolinska Institutet
Giacomo Koch
Santa Lucia Foundation
Russell Lebovitz
Amprion Inc.
Frank Longo
Stanford Univ./PharmatropiX
Dawn Matthews
ADMdx
Bradford Navia
Aprinoia
Laura Nisenbaum
ADDF
Miranda Orr
Wake Forest University
Meriel Owen
ADDF
Mark Roithmayr
ADDF
Marwan Sabbagh
Barrow Neurological Institute
Philip Scheltens
EQT Life Sciences
Jeffrey Stavenhagen
Therini Bio
Ronald van der Geest
Treeway
Tim West
C2N
ORGANIZING COMMITTEE
Howard Fillit
Alzheimer’s Drug Discovery Foundation
Laura Nisenbaum
Alzheimer’s Drug Discovery Foundation
Aaron Burstein
Alzheimer’s Drug Discovery Foundation
Meriel Owen
Alzheimer’s Drug Discovery Foundation
CONTACT
For any questions, please contact ADDF Meetings at meetings@alzdiscovery.org.